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Abstract: Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological
malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only
modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel
therapies are urgently needed. The presence of tumor-infiltrating lymphocytes (TILs) in OC tumor
microenvironment (TME) has already proved to be correlated with overall survival (OS), while
immune evasion mechanisms are associated with poor prognosis. Although these data indicate that
immunotherapy has a strong rationale in OC, single agent immune-checkpoints inhibitors (ICIs) have
shown only modest results in this malignancy. In this review, we will discuss immune-targeting
combination therapies and adoptive cell therapy (ACT), highlighting the challenges represented by
these strategies, which aim at disrupting the stroma-tumor barrier to boost immune system against
ovarian cancer.
Keywords: ovarian cancer; immunotherapy; adoptive cell therapy; tumor infiltrating-lymphocytes;
tumor microenvironment
1. Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death among women with gynecological
malignancies with 22,530 estimated new cases and 13,980 deaths in 2019 in the USA [1]. Surgery and
chemotherapy, based on carboplatin and paclitaxel, have been long established as the cornerstone for
the primary management of EOC [2].
However, despite multimodal treatment and the transforming advance represented by the
introduction of agents targeting poly (ADP-ribose) polymerase (PARP) [3], prognosis is still poor for
advanced stages and survival rates have improved only modestly over the past few decades [4].
EOC has traditionally been considered as scarcely immunogenic. However, several findings
contradict this statement, such as spontaneous tumor regressions [5,6], evidence of mechanisms of
immune evasion and occasional durable responses to immune checkpoints-inhibitors (ICIs) [7].
Notably, BRCA1/2-mutated high-grade serous ovarian cancers (HGSOCs) exhibit a higher
mutational load and a unique mutational signature with a significantly increased number of
tumor-infiltrating lymphocytes (TILs), as well as elevated expression of programmed cell death (PD-1)
or its ligand (PD-L1) in tumor-associated immune cells compared to homologous-recombination
(HR)-proficient tumors [8,9]. Furthermore, patients with T-cell-rich tumors experience longer
progression-free and overall survival [10], while immune evasion mechanisms are associated with
poor survival [11–15]. All these evidences taken together suggest that EOC patients could potentially
benefit from immunotherapy.
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Despite the encouraging results in melanoma, non-small cell lung cancer (NSCLC), kidney
and urothelial cancers [16,17], the use of single-agent antibodies inhibiting the cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) or PD-1 or PD-L1 axis yielded only modest results in EOC
with median response rates of 10–15%, and a control of disease observed in less than half of the
patients [18–21].
Interestingly, the combination of the anti-PD1 nivolumab and anti-CTLA4 ipilimumab showed
promising results in platinum resistant EOC at the six months-interim analyses with an overall
response rate (ORR) of 34% (doubling the results of nivolumab monotherapy). However, data are still
immature [22].
As a consequence, no immunotherapeutic agent has obtained regulatory approval for EOC thus far.
Many strategies to overcome resistance to ICIs are currently under investigation and the
tumor–immune system interaction is now considered a key element guiding the research toward more
personalized approaches.
According to the status of TILs infiltration, tumors could be histologically categorized as
“inflamed/hot tumors” or “non-inflamed/cold”. The first ones are characterized by the presence
in the tumor bed of a high density of CD8+ T cells [23,24], whose functionality can be impaired by
immunosuppressive networks. Such patients could benefit from therapies acting on T cell checkpoint
involved in immune-tolerance.
On the contrary, cold tumors are characterized by the absence of T cells in tumor beds and at
tumor edges and are generally affected by a failure in T cell priming reflecting the need of strategies
that could deliver autologous/allogenic effector cells into the cancer.
A third phenotype, defined as “immune-excluded”, is characterized by the modification of tumor
microenvironment (TME) and the presence of inhibitory cells that retain CD8 T cells from entering the
tumor islets, even if they are present in the stroma. Such patients could benefit from strategies whose
aim is to increase infiltrations of tumors by immune effector cells such as T cell trafficking modulators,
epigenetic modulators, TME remodeling molecules, radiation therapy [25].
In this review, we focus on the strategies and challenges represented by immune-targeting
combinations in the most advanced stages of development in EOC. We also describe challenges and
advances in adoptive cell therapy (ACT) which, despite the limited data available in EOC so far,
represent a unique opportunity to enhance immune-response “heating the fire” against OC (Figure 1).
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Figure 1. Rep sentative scheme of combination therapies ap roac d adoptive cell therapy (ACT)
in OC.
PARP inhibitors (PARPIs) and immune-checkpoints inhibithors (ICIs) promote the release of
pro-inflammatory signals and the expression of co-stimulatory molecules, expand the neoantigens
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repertoire and indeed increase the visibility of tumor cells to T cells. Anti-vascular endothelial grow
factor (anti-VEGF) agents normalize the vascular structure of the tumor microenviroment (TME)
regulating T cells infiltration and trafficking and contribuiting to dendritic cells (DCs) maturation and
downregulation of the PD-L1 pathway expression. ACT (a): Tumor-infiltrating lymphocites (TILs)
are isolated from surgically resected tumor samples, then expanded in vitro and reinfused into the
lymphodepleted patient; (b): T cells from patient peripheral blood are isolated and expanded in culture
and genetically modified to express either a T cell receptor (TCR) or a chimeric antigen receptor (CAR)
that confers the ability to specifically recognize and destroy tumor-cells when re-infused into the the
lymphodepleted patient.
2. Combination Therapies
2.1. Check-Point Inhibitors and Anti-VEGF Therapy
Ovarian TME consists of blood and lymphatic vessels and of different types of stromal cells
embedded in the omental extracellular matrix. These cells can act as immune modulators and comprise
myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), adipocytes, CAFs
(cancer activated fibroblasts) and resident and infiltrating immune cells, including regulatory T cells (Treg).
Tumor vessels are abnormal, both structurally and functionally, and favor an immunosuppressive
environment characterized by hypoxia, low pH and high interstitial fluid pressure due to dysfunctional
lymphatic drainage.
An abnormal TME promotes the activation and expansion of immunosuppressive Treg cells and
the recruitment of TAMs, the expansion of abnormal endothelial cells (ECs), and the suppression of
dendritic cell (DC) maturation, which in turn results in impaired antigen presentation and activation
of tumor-specific cytotoxic lymphocytes. Importantly, the PD-1/PD-L1 pathway is often upregulated
both on tumor cells and on tumor-infiltrating CTLs, marking them as dysfunctional or ‘exhausted’ and
limiting their cytotoxic potential [26]. Furthermore, the vascular endothelial grow factor (VEGF) can
promote the expansion of MDSCs and enhance their immunosuppressive function in the TME. [27,28].
Thus, there is a strong rationale in combining antiangiogenic therapies and ICIs and, in fact, many
phase 3 trials are currently ongoing. Antiangiogenics might partially increase the effectiveness of
immunotherapy through the normalization of the abnormal tumor vasculature and contrasting the
direct inhibitory effect on immune and endothelial cells, increasing the infiltration of immune effector
cells into tumors and converting the intrinsically immunosuppressive TME to an immune-supportive
one [29].
In 2017, Lee et al. [30] conducted a phase 1 basket trial to evaluate the antitumor effect of the PD-1
inhibitor durvalumab in combination with endothelial growth factor receptor 1–3 inhibitor cediranib or
PARP inhibitor olaparib in women with solid tumors. A total of nine patients with EOC were treated in
the durvalumab plus cediranib arm. Five patients had a partial response (PR) with an overall response
rate (ORR) of about 55%, which is higher compared with that recorded for PD-L1 pathway inhibition
(10–20% ORR) [18] or cediranib treatment alone (23% ORR) [31]. However, treatment with durvalumab
plus cediranib was associated with a higher frequency of adverse events (AEs). Continuous cediranib
was not tolerated due to hypertension and diarrhea (seven patients suffered from grade 2–4 AEs and one
patient experienced grade 3 pulmonary hypertension and eventually died from pulmonary embolism).
More recently, Liu et al. presented at ESMO 2018 [32] the encouraging preliminary results of
the phase II trial evaluating the combination of anti-PD1 nivolumab and bevacizumab in 38 patients
affected by EOC, including 18 with platinum-resistant disease. The combinatorial treatment shows
an ORR of 28.9% (40% and 16.7% in the platinum-sensitive and in the platinum-resistant cohort
respectively) with a median PFS of 8.1 months and no unexpected AEs.
Thus, bevacizumab seems to be a safe and tolerable anti-VEGF drug to be associated to checkpoint
blockade to enhance immuno-response and currently three phase 3 trials are ongoing both in front-line
and recurrence settings (Table 1).
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Table 1. Ongoing phase III clinical trials exploring CPIs and anti- vascular endothelial grow factor (VEGF).
Trial Name NCT Code Setting Patients’ selection Arms Primary Endpoints
GOG3015/ENGOT OV39 NCT03038100 Front line
• Stage III or IV
• PDS or IDS any residual
• Stratification PD-L1 0 vs 1+
• Carbo-Tax + Bev
• Carbo-Tax + Bev + Atezo
• PFS and PFS in PD-L1 + subpop
• OS and OS in PD-L1 + subpop
ATALANTE/ENGOT
OV29 NCT02891824 Recurrence
• 1 or 2 previous CT lines
• PFI > 6 months
• Stratification PD-L1
• Carbo combo + Bev
• Carbo combo + Bev + Atezo PFS
EORTC-1508 NCT02659384 Recurrence
• Platinum resistant
• Any num of platinum lines
• Max 2 lines non-platinum
• Biopsy required
• Bev + aspirin
• Bev + Atezo + aspirin
• Bev + Atezo + placebo
• Atezo + aspirin
• Atezo + placebo
PFS at 6 months
PDS: Primary debulking surgery; IDS: Interval debulking surgery; PD-L1: Programmed death-ligand 1; CT: Chemotherapy; PFI: Platinum-free interval; num: Number; max: Maximum;
Carbo: Carboplatin; Tax: Taxol; Bev: Bevacizumab; Atezo: Atezolizumab; combo: Combination; PFS: Progression-free survival; subpop: Subpopulation; OS: Overall survival.
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2.2. Check-Point Inhibitors and PARP-Inhibitors
The landscape of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPIs) is rapidly evolving and
represents a cornerstone in the natural history of EOC. Since 2014 the Food and Drug Administration
(FDA) and the European Medicine Agency (EMA) have approved three PARPIs for the treatment of
EOC [33–38].
PARP proteins catalyze the polymerization of poly (ADP-ribose) on proteins. This reversible
post-translational modification of proteins, also called PARylation, is implicated in many cellular
mechanisms, notably DNA repair. PARP detects single-strand breaks (SSBs) and, through its PARylation
activity, recruits proteins that mediate DNA repair. Furthermore, PARP-1 shows wide immune effects:
i) Regulation of DCs maturation from monocytes; ii) reduction of CD86 and CD83 and of IL-12 and
IL-10 expression; iii) modulation of the activation of nuclear factor of activated T cell (NFAT) which is
essential in T cell function. [39–41]
As stated before, EOC with BRCA1/2 mutation has been identified as an ideal candidate for
immunotherapy and PARPIs combination. In HGSOC, tumors harboring HR-deficient/BRCA1/2
mutations demonstrated a higher neoantigen load and increased numbers of CD3+ and CD8+ TILs [42].
Elevated levels of PD-1 and PD-L1 expression on TILs were also observed compared with that in
HR-proficient tumors, which indicated that BRCA1/2-mutated HGSOCs may be more sensitive to
PD-1/PD-L1 inhibitors compared with HR-proficient ones.
A phase I study to evaluate the safety and efficacy of the combination of PARP inhibitor and
anti-CTLA-4 antibody was conducted in women with BRCA mutation-associated recurrent OC [43]. No
dose-limiting toxicities were identified and grade 1/2 toxicities were consistent with prior studies that
used immune checkpoint inhibitors. More recently, two studies exploring different combinations were
presented at ASCO 2018. The first one by Konstantinopoulos et al. was a phase 1/2 study evaluating
niraparib and pembrolizumab [44]. Interestingly, ORR was 23% without any significant difference in
biomarkers selected populations (25% in BRCA-mutated and 24% in BRCA wild-type respectively).
The second one, already published [45], combined olaparib and durvalumab in platinum-sensitive
relapsed BRCA mutated EOC. Overall, 23 of 32 patients had objective responses with olaparib plus
durvalumab, including six (19%) complete responses. Subgroup analysis showed a consistency of
response in patients who had received up to three prior lines of therapy. The combination achieved a
12-week disease-control rate (DCR) of 81%. Furthermore, six patients had complete responses (CR) and
17 others had PRs resulting in an ORR of 72%. An additional three patients had SD, bringing the DCR
to 81%. The combination was well tolerated, with a low incidence of grade 3 or higher AEs or all-grade
immune-related adverse events (irAE). The most common irAEs (all grades) were hypothyroidism in
five (15%) patients and rash in four (12%). Finally, the study presented by Lee et al. (durvalumab and
olaparib in recurrent EOC) at ESMO 2018 did not meet the primary endpoint with an overall DCR of
37% and only 5/35 (14%) PR [46].
The above results suggest that the combinations of PARPIs and PD-1/PD-L1 blockade seem
to enhance the antitumor effect without significantly increasing toxicity and support their further
development in EOC independently from BRCA mutational status.
Ongoing phase III trials exploring ICIs and PARPIs combinations are listed in Table 2.
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Table 2. Ongoing phase III clinical trials exploring combination of CPIs and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPIs).
Trial Name NCT Code Setting Patients’ Selection Arms Endpoints
AGO/DUO-ENGOT Ov46 NCT03737643 Front line
• BRCA non-mut
• PDS or IDS any residual
• LGSOC excluded
• Carbo-tax+Bev+placebo+palcebo
• Carbo-tax+Bev+durvalumab+placebo
• Carbo-tax+Bev+durvalumab+olaparib
PFS in BRCA non-mut
BGOG/ENGOT Ov43 NCT03740165 Front line
• BRCA non-mut
• any histotype
• PDS or IDS any residual
• Bev optional
• Carbo-tax+placebo+placebo
• Carbo-tax+pembrolizumab+placebo
• Carbo-tax+pembrolizumab+olaparib
PFS, OS
GINECO/FIRST ENGOT
Ov44 NCT03602859 Front line
• PDS or IDS
• Mucinous excluded
• Bev optional
• Carbo-tax+palcebo+placebo
• Carbo-tax+placebo+niraparib
• Carbo-tax+TSR042+niraparib
PFS
ATHENA
GOG3020/ENGOT Ov45 NCT03522246
Maintenance after
front line
• Stage III-IV HGSOC
• PDS or IDS
• Response to platinum
• Rucaparib-nivolumab
• Rucaparib-placebo
• Nivolumab-placebo
• Placebo-placebo
PFS
BRCA: Breast cancer related genes; PDS: Primary debulking surgery; IDS: Interval debulking surgery; LGSOC: Low grade serous ovarian cancer; HGSOC: High-grade serous ovarian
cancer; Carbo: Carboplatin; Tax: Taxol; Bev: Bevacizumab; PFS: Progression-free survival; OS: Overall survival.
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2.3. Adoptive Immunotherapies
Adoptive immunotherapy is emerging as an active treatment in cancers that are less responsive or
refractory to ICIs. This approach is based on the infusion of autologous or allogenic immune effectors
that destroy tumor cells.
Currently one of the most promising approach in solid cancers is represented by ACT, in
which tumor-specific cytotoxic T cells, either isolated from the tumor or in the peripheral blood by
leukapheresis, are expanded in vivo and then infused after lymphodepleting chemotherapy.
EOC is characterized by a low/intermediate mutational burden [47,48]. However, several
experiences have shown that these tumors can harbor missense somatic mutations that can serve as
neoantigens and elicit tumor specific T cells that could be exploited for ACT.
In a prospective series, authors showed that in five out of seven cases, EOC metastases from
immunotherapy naïve patients are infiltrated by mutation reactive T cells (mainly against mutant p53),
thus at frequencies that are encouraging toward future use in adoptive therapies [49].
In another work, Bobisse et al. reported the identification of neo-epitope specific CD8+ T cells in
~90% of evaluated patients, with a notably higher functional avidity in TILs compared to circulating T
lymphocytes and different TCR repertoires [50].
Westergaard et al., successfully established and expanded TILs from 34 tumors specimen of OC
and demonstrated the recognition of autologous tumor cell in >50% of the patients. Furthermore,
antigen specific TILs were isolated and further expanded in vivo [51].
Taken together these preclinical data support the development of ACT in EOC.
First evidences of possible activity of ACT in EOC derives from first line, non-randomized phase
1 study in which TILs were administered in 13 patients with no evidence of disease after surgical
resection and cisplatin-based chemotherapy. Eleven patients with the same characteristics were treated
with chemotherapy only and served as control arm. The 3-year overall survival rates were shown to be
higher in the TILs group (100% compared to 67.5%, respectively) [52].
Recently, results from a pilot study in platinum resistant OC with lympho-depleting chemotherapy
followed by the infusion of unselected TILS and IL2 were published. The therapy was feasible and with
no unexpected toxicities related to high dose chemotherapy or the administration of IL2. There were
signs of antitumor reactivity in TILs infusion products but clinical results are still not satisfactory
since patients achieved only SD as best response for three to five months. Authors specify that a high
percentage of infused TILs expressed exhaustion markers with tumor tissue expressing inhibitory
immune checkpoint ligands. These findings open the road toward the possibility of enhancing ACT
combining it to ICIs [53].
Other possible strategies could be applied to enhance efficacy of adoptive therapies.
First, although considered as immunosuppressive for several decades, it is now known that
chemotherapy could improve immunotherapy efficacy, acting on several factors, such as T cells
trafficking, neo-antigen presentations and TME. Indeed several studies indicate that also in OC
neoadjuvant chemotherapy (NACT) enhance CD8 + TILs infiltration and activity and may reduce
Tregs [54–56]. In the most recent Lo et al. show that NACT increased pre-existing TIL responses
(in already TILs-infiltrated tumor) but with scant effect on cold tumors and on immunosuppressing
cells [57]. Thus, this evidence suggests that the optimal timing for TILs collection should be further
investigated, possibly being different in inflamed- and non-inflamed tumors to maximize TILs vitality
and activity when infused.
Second, activity of ACT could be enhanced with the use of antigen selected TILs, that has
proven feasible in OC [51] or by genetically engineering T cells to express either an exogenous tumor
antigen-specific T cell receptor (TCR) or a chimeric antigen receptor (CAR).
In the first case the TCR is engineered to have a higher affinity for both intracellular and
extracellular targets but T-cell activity is still dependent on the antigen presentation and expression
of MHC that can be impaired in tumor tissue. Additionally, TCR activity is also MHC haplotype
restricted. Furthermore, T cells can be isolated from the patient’s peripheral blood and engineered
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with a specific receptor to target a known TAA on the patient’s tumor. This allows the generation of
a highly specific T cell that can be obtained from peripheral blood, avoiding tumor extraction and
expansion of TILS and also theoretically limiting toxicities.
In contrast, CARs are engineered so that they can recognize an antigen in a MHC independent
fashion through an antigen specific extracellular antibody single chain variable fragment (scFv) but is
thus limited to surface antigens.
Several clinical trials using engineered T cells to target antigens in OC, such as NY-ESO-1, HER2,
FR-alpha, MSLN, MUC16, and p53 are currently recruiting in solid cancers (Table 3).
Despite good in vitro and in vivo activity of anti-folate receptor (Fr) alpha CAR T cells, the first
phase 1 trials in metastatic OC patients failed to show any sign of activity [58]. Possible reasons,
according to authors, are scarce T cell trafficking and persistence of cell in the tumor. New generation
CAR-T comprehensive of costimulatory signaling domain have shown greater persistence and efficacy
in vivo and in vitro models of OC [59].
Targeting FR-alpha with cell-based therapies, drugs or vaccines are generally well tolerated
and seemed promising showing early signs of responses with Bi-specific T-cell engaging (BiTE)
antibodies [60]. Furthermore, since it is expressed by the vast majority of HGSOC at much higher
levels than healthy ovarian tissue, it represents an ideal candidate for immunotherapy.
Mesothelin is another promising target that is expressed in about 70% of epithelial OC [61].
Preliminary results of second generation anti mesothelin CAR T in OC are encouraging: The therapy
was feasible and safe, the CAR T-meso cells engrafted and expanded in the blood of all subjects.
There was evidence of trafficking to tumor sites resulting in the clearance of pleural effusion in one
patient and in stabilization of disease in all six patients [62].
Exploiting the innate immune system is the base of adoptive-non-antigen-based strategies,
consisting in the infusion of natural killer (NK) or cytokine-induced killer cells (CIK) cells. Use of
these cells could have several advantages, such as the independence from MHC and from prior
sensitization to the antigen. These therapies have proven to be feasible but research is still at an early
stage. With regards to NK adoptive therapy, a first phase 2 trial with haploidentical allogenic NK cells
showed scarce persistence of NK in the donor, with no relevant clinical activity [63]. In a phase I trial
two patients with ovarian cancer were treated with allogenic haploidentical NK cells. Best responses
were SD and PD [64], while in a case report patient achieved a PR with biomarker response after
six treatments.
These studies suggest that allogeneic NK cell therapy is feasible although further efforts that will
generate novel strategies to increase in vivo NK cell persistence and expansion after adoptive transfer
are needed.
CIK cells are a group of immune effector cells with cytotoxic activity that can be rapidly proliferated
in vitro from PBMC after incubation with different cytokines (IFN Y, IL2, IL1 and anti CD3). The main
effectors of CIK cells are the NK-like T lymphocytes (CD3+ CD56+) that have potentially enhanced
and broader antitumor activity compared to TILS and do not depend from TCR and MHC activity
but still can elicit both MHC-restricted and MHC-unrestricted anti-tumor citotoxicity [65]. Such cells
showed to be very active against ovarian cancer in vitro and in vivo [66] and also showed enhanced
activity and better tolerability compared to LAK cells (PBMC incubated with IL2), that demonstrated
limited clinical efficacy with high rates of peritoneal fibrosis when given intraperitoneally [67–69].
There are signals that CIKs could be useful in the adjuvant setting, but further evidences are
needed [70].
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Table 3. Selected trials of adoptive therapies in epithelial ovarian cancer (EOC).
Therapy NCT Code Phase Patients’ Selection Primary Endpoint(s)
TILs, IL2 and pembrolizumab after Cy NCT03158935 I • Platinum resistant SAE within 35 days of TIL infusion
TILs and IL2 after Cy and F with prior treatment
with ipilimumab and nivolumab NCT03287674 I/II
• Platinum resistant
• If platinum sensitive ≥ 2 previous lines AE
Cy and TAEST16001
(NY-ESO1 specific TCR-T cell) NCT03159585 I
• Further lines
• HLA-A*0201 POSITIVE
• NY-ESO-1 positive cells≥25% by IHC
AE (30 days)
Genetically engeneered NY-ESO-1 specific
lymphocycites
(IV et IP), aldesleukin after Cy and decitabine
NCT03017131 I
• Platinum resistant
• If platinum sensitive ≥2 previous lines
• HLA-A*0201 POSITIVE
AE (28 days)
TBI-1201 (MAGE-A4-specific TCR transduced
T lymphocites) after Cy and F NCT02096614 I
• HLA-A*24:02 positive
• MAGE-A4-expression by PCR or IHC /
4H11-28z/fIL-12/EGFRt+ Genetically-modified
T cells after Cy NCT02498912 I
• Further lines
• MUC16ecto positive tumors in IHC
(score 3–5)
MTD (30 days)
Anti-mesothelin CAR transduced PBL and
aldesleukin after Cy and F NCT01583686 I/II
• Further lines AE (5 years), ORR
Anti-HER2 CAR-T cells NCT02713984 I/II
• Further lines
• HER2+ cells AE
TILs: Tumor infiltrating lymphocytes; IL-2: Interleukin-2; Cy: Cyclophosphamide; F: Fludarabine; IV: Intravenously; IP: Intraperitoneally; AE: Adverse events; TCR: T cell receptor; CAR-T:
Chimeric antigen receptor-T cell; PBL: Peripheral blood lymphocytes.
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3. Patients’ Selection
As discussed, inhibition of checkpoint PD-1/PDL1 and CTLA 4 axis produces low response rates in
unselected ovarian cancer patients, as the majority of clinical trials so far have been recruiting patients
without distinction between inflamed- and excluded-tumors.
Currently, biomarkers like PD-L1 expression, TMB and TILs infiltration have not yet proven to be
useful for patient selection in OC. While expression of PD-L1 on tumor cells is a predictive biomarker
of response to ICIs in other cancer types (i.e., NSCLC and urothelial cancers), its expression in EOC is
not very frequent (10–33%) [71,72] suggesting that not all tumors rely on this pathway for immune
evasion and its prognostic role in EOC is still controverted. Some data suggest that high expression of
PD-L1 correlates with worse prognosis [73,74], while in other series a higher expression correlates with
better PFS [75–77].
High levels of CD8+ TILs are known to be associated with better prognosis [10], as well as the
presence of other immune cells such as CD4+ T cells [78], memory B cells [79] and plasma cells [80].
However, their presence has not proven to be predictive biomarkers of response to ICIs. Zhang et al.
showed that epithelial CD8+ TILs correlates with neoantigens selection and high rates of HLA
expression loss, thus suggesting a strong immune-editing in the TME. The neoantigen depletion and
the impaired presentation together with the tumor heterogeneity and the clonal evolutions of tumor in
different metastatic sites could influence immunosurveillance and the response to ICIs of the so-called
“inflamed tumors” [81].
Mutational status of EOC could predict immunogenicity. As already mentioned, tumor with
homologous-recombination deficiency (HRD) have a higher predicted neo-antigen load and higher
TILs infiltration. However clinical data shows that response to ICI monotherapies is rare in BRCA
mutated patients as well, indicating that neoantigen load is not a good selection strategy, but also
opening the road for combination therapies with PARPIs.
Furthermore, a recent analysis on the Keynote-100 showed no statistically significant differences
in HRD status among responders and non-responders and the absence of association between BRCA
status and responses. Interestingly, TMB and T cell-inflamed gene expression profile (GEP) were
independently predictive of response and demonstrated low correlation, suggesting that they capture
distinct features of neo-antigenicity and T cell activation [82,83].
4. Conclusions
New and more effective treatment modalities of immunotherapy are being investigated in EOC
based on tumor biology, its relationship with TME and the immune-suppressive networks that make
this cancer difficult to tackle with single agent ICIs.
Specific antigens such as NY-ESO-1, FR-alpha, MSLN, MUC16, and p53 are attractive
immunotherapy targets, due to their frequent expression in OC and are currently under investigation
in different modalities such as vaccines [84], oncolytic viral platforms, combination therapies with ICIs
or chemotherapies [84–86] and as TAAs in adoptive cellular immunotherapy [87].
TME plays a crucial role in the immune-suppression and immune-tolerance that can impair the
presence and the activity of TILs, such as the presence of Tregs, TAMs, MDSC, exosomes, adipocytes and
CAFs. All these TME’s components should be taken into account when designing novel therapeutic
strategies, in particular for the immune-excluded/“cold tumors”. These may include strategies to
prime T cell responses, including vaccines and ACT directed to neo-antigens presented by tumor cells;
inducers of immunogenic cell death in strategies of in situ vaccination and simultaneous targeting of
checkpoint inhibitors responsible for T cell anergy and/or exhaustion.
Finally, targeting other immunosuppressive pathway could be a way to enhance responses to
immunotherapy. Among those, one of the most dominant immune resistance mechanismsin EOC is
mediated by indole-amine-2,3-dioxygenase (IDO), an enzyme that catalyzes the tryptophan degradation
along the kynurenine pathway and enhances the synthesis of immunosuppressive metabolites [84].
Inhibition of this pathway is being explored in different tumors.
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The autologous infusion of enriched naturally occurring tumor reactive lymphocytes could be
a way to improve immunotherapy efficacy in already infiltrated tumors. Advances in genetically
engineering and new generation of TCR or CAR modified T cells could represent a real game changer
in these cancers.
So far, TIL-based therapies have only been offered in small phase I/II studies in a few highly
specialized centers mastering the complexity of TIL production and the very intensive nature of the
three-step treatment protocol. Despite the limited data available in OC, we believe that this strategy is
a unique opportunity to enhance immune-response “heating the fire” against OC.
A better characterization of the tumor and stromal environment, which shuts out TILs in
immune-excluded EOCs, is critical in order to identify reliable predictive biomarkers and advance the
field of immunotherapy in this malignancy. In conclusion, understanding the tumor immune escape
mechanisms will enable a greater sophistication in immunotherapy treatments allowing tailoring
treatment not only according to tumor biology but also to TME characteristics, extending the benefit of
immunotherapy to more patients and hopefully providing long-lasting durable responses.
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